Journal article icon

Journal article

Improved survival with MEK inhibition in BRAF-mutated melanoma.

Abstract:

BACKGROUND: Activating mutations in serine-threonine protein kinase B-RAF (BRAF) are found in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy improves survival, as compared with chemotherapy, but responses are often short-lived. In previous trials, MEK inhibition appeared to be promising in this population. METHODS: In this phase 3 open-label trial, we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation to receive either tra...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1056/nejmoa1203421

Authors


Flaherty, KT More by this author
Expand authors...
Journal:
The New England journal of medicine
Volume:
367
Issue:
2
Pages:
107-114
Publication date:
2012-07-05
DOI:
EISSN:
1533-4406
ISSN:
0028-4793
URN:
uuid:17a4cd0c-72ea-46f7-ab36-457c375b3557
Source identifiers:
344638
Local pid:
pubs:344638

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP